Xiuping Yu, PhD

Having transitioned from a surgeon to a cancer researcher, I have acquired invaluable clinical experience, enabling me to grasp the challenges faced by cancer patients. This experience has ignited my passion to translate research findings into practical applications that directly benefit patients. Throughout my career, my focus has been on translational research in breast cancer and colorectal cancer, delving into the underlying mechanisms of cancer initiation and progression, while devising effective strategies to impede these processes.

Currently, my research is concentrated on cancer drug development and the investigation of molecular mechanisms involving microRNA in the anti-cancer effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Extensive studies have established NSAIDs as a significant class of agents exhibiting pleiotropic antineoplastic activities, including hindering tumor cell proliferation, inducing apoptosis, and suppressing angiogenesis. Notably, our particular interest lies in exploring the potential of NSAIDs as novel immune modulators to enhance the response of triple negative breast cancer and colorectal cancer to immune checkpoint inhibitors.

Education: MD, PhD, MBA

ORCID identifier: 0000-0003-3681-9352

MyNCBI Link: http://www.ncbi.nlm.nih.gov/myncbi/yaguang.xi.1/bibliography/43243855/public/?sort=date&direction=ascending

Selected Publications:

 
• Bin Yi, Yu Xun, Hao      Cheng, Qingzhao Yu, Augusto Ochoa, Adam Riker, Yaguang Xi*. 2021. Sulindac      modulates the response of proficient MMR colorectal cancer to anti-PD-L1      immunotherapy. Molecular Cancer Therapeutics. 20(7):1295-1304.      
 
• Hongyou Zhao, Bin Yi,      Zhipin Liang, Ches’Nique Phillips, Hui-Yi Lin, Adam I. Riker, Yaguang      Xi*. 2021. Cyclin G2, a novel target of sulindac to inhibit cell      cycle progression in colorectal cancer. Genes and Diseases.      8 (3): 320-330.
 
• Zhipin Liang, Zhiqiang      Qin, Adam Riker, Yaguang      Xi*.2020. CRISPR/Cas9 ablating viral microRNA promotes      lytic reactivation of Kaposi's sarcoma-associated herpesvirus. Biochem Biophys Res Commun.      533(4):1400-1405.
 
• Xiaobo Li, Junwu Zhang,      Lin Gao, Steve McClellan, Michael A. Finan, Thomas W. Butler, Laurie B.      Owen, Gary A. Piazza, Yaguang Xi*.2012. MiR-181 mediates cell      differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell      Death & Differentiation. 19(3):378-386.
 
• Xiaobo Li, Lin Gao,      Qinghua Cui, Bernard D. Gary, Donna Lynn Dyess, William Taylor, Lalita A.      Shevde, Rajeev S. Samant, Windy Dean-Colomb, Gary A. Piazza, Yaguang      Xi*.2012. Sulindac inhibits tumor cell invasion by suppressing NF-κB      mediated transcription of microRNAs. Oncogene.      31(48):4979-86

Keywords/Tags: Cancer Therapeutics, Cancer Chemoprevention, Tumor Metastasis, Cancer Drug Discovery and Development, Health Disparities, Immunotherapy.

Link to lab website: https://www.medschool.lsuhsc.edu/genetics/faculty_detail.aspx?name=Xi_Yaguang

‍

‍